visions act

The VISIONS Act, Psilocybin and Federal Enforcement

Perhaps inevitably, lawmakers introduced a very skinny bill last week to protect states that legalize psilocybin from federal intervention. Specifically, it requires that: [n]o Federal funds may be used to prevent any State or unit of local government from implementing such State’s or unit of local government’s own laws that authorize the use, distribution, sale,

fda approval

Will Psychedelics Be Rescheduled After FDA Approval?

A handful of entities are in various stages of the FDA approval process for MDMA and psilocybin drugs (see here and here for some of our prior analysis of the issues). FDA approval could happen in the next few years. But there’s a catch: psilocybin and MDMA are both schedule I drugs under the Controlled Substances Act (CSA).

oregon psilocybin laws

Oregon’s New Psilocybin Laws (Data Collection)

At the kickoff of the Oregon legislative session in January, I wrote Oregon Psilocybin 2023: Legislative Forecast and Report. The session went awry in April, when Oregon Senate Republicans staged a walkout over gun and abortion bills. The walkout lasted six weeks, with our representatives re-opening for business on June 15th— just 10 days before sin die on

psychedelics industry

Making Money in the Psychedelics Industry Will be Harder than Cannabis

Anyone familiar with the cannabis industry knows how difficult it is to make money. Things are going to be even worse for people in the state-legal psychedelics industry – much worse. There are a few key reasons for this. I should note that this post is focused on the state-legal psychedelics industry (i.e., service centers)

magic mushrooms

Magic Mushrooms: The Newest Treatment for Athletes?

The use of psilocybin (magic mushrooms) for therapeutic purposes gains traction Last month, the NBA and its players association reached a tentative deal that the league would no longer test players for marijuana. Indeed, the NBA is lifting its ban on marijuana in the new collective bargaining agreement.  Meanwhile, the NFL and its players agreed

washington psilocybin

Washington Psilocybin Bill Awaits Governor’s Approval

Washington’s House and Senate have both approved the “Washington Psilocybin Services Act” (SB 5263) and the bill awaits Governor Jay Inslee’s signature. Psilocybin is a schedule I drug under the federal Controlled Substances Act and is the psychoactive or “hallucinogenic” component of magic mushrooms. Washington appears set to follow in the footsteps of Oregon and

hall of shame

The Psychedelics Company Structure Hall of Shame (with Pictures)

The Oregon psilocybin program has a residency requirement. I explained how it works here, and wrote “queue the crazy business structures.” Because the program is off to a slow start (see here and here) I haven’t received as many crazy requests as expected. Well, that changed last week when I received a proposal that made

oregon psilocybin license

Oregon Issues First Psilocybin Licenses. Now What?

Last week, the Oregon Health Authority (OHA) awarded a pair of psilocybin manufacturer licenses. First two! Congrats to Tori Arbrust of Satori Farms PDX, and Andres Met of Satya Therapeutics, known to many of us from the Oregon cannabis program. We should also congratulate OHA, which had aimed to issue manufacturing licenses by the end

free webinar

FREE WEBINAR: Ketamine Regulations & The Future of Therapeutic Psychedelic Medicines

Click HERE to register for our upcoming FREE Q&A webinar on ketamine regulations and the future of therapeutic psychedelic medicines! In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that

therapeutic use

Psilocybin and MDMA — Therapeutic Use Permitted in Australia from July 1st 2023

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Commonly found in tablet or crystal form, MDMA is a potent psychoactive drug with stimulant properties that produces experiences of empathy and sympathy. Both are currently prohibited in Australia, but will soon be available for therapeutic use. In so